Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: While not available for clinical use in the United States, dedicated drug-coated balloons (DCB) are currently under investigation for the management of coronary in-stent restenosis (ISR). Peripheral drug-coated balloons (P-DCB) have been used off-label for coronary ISR. Further data regarding this practice are needed. We aimed to describe outcomes in patients who underwent off-label P-DCB angioplasty for coronary ISR.
Methods: We analyzed data on P-DCB angioplasty for coronary ISR at a single high-volume center between April 1, 2015, and December 30, 2017. Demographic and procedural details were collected, with systematic follow-up as clinically indicated.
Results: Data from 31 patients treated with P-DCB angioplasty (mean age 68.0 ± 10.7 years) with coronary ISR (17 recurrent and 14 first time) were analyzed. Most patients presented with high-grade angina (81%) or myocardial infarction (13%). Treated ISR lesions were in native coronary arteries (68%), saphenous vein grafts (SVG, 23%), and the left internal mammary artery (10%). Diffuse intrastent ISR was common (69%) with a mean lesion length of 21.7 ± 12.4 mm. No postprocedural myocardial infarction occurred and 1 nonprocedural mortality occurred during index admission. At follow-up (median: 283, interquartile range [IQR]: 354 days), repeat angiography was performed in 19 patients (median: 212, IQR: 188 days), and 11 patients had target lesion recurrent ISR (Kaplan-Meier event-free survival estimate: 44.7%, 95% CI, 26.1%-76.5%).
Conclusions: In the absence of availability of dedicated coronary DCB, treatment of coronary ISR using P-DCB angioplasty was feasible, although follow-up demonstrated continued risk for recurrent ISR in this high-risk population.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11307773 | PMC |
| http://dx.doi.org/10.1016/j.jscai.2023.101262 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Background: The lncRNA-miRNA-mRNA regulatory network is recognized for its significant role in cardiovascular diseases, yet its involvement in in-stent restenosis (ISR) remains unexplored. Our study aimed to investigate how this regulatory network influences ISR occurrence and development by modulating inflammation and immunity.
Methods: By utilizing data extracted from the Gene Expression Omnibus (GEO) database, we constructed the lncRNA-miRNA-mRNA regulatory network specific to ISR.
Research status and trends of drug-coated balloons in coronary artery disease: a bibliometric analysis.
Front Med (Lausanne)
August 2025
Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
Objective: Drug-coated balloons have emerged as a pivotal alternative to drug-eluting stents in the interventional management of coronary artery disease, particularly showing clinical advantages in the treatment of in-stent restenosis and small-vessel disease. This study provides a systematic bibliometric analysis of publication trends, research hotspots, and future directions in DCB-related CAD research from 2004 to June 2025.
Methods: A total of 1,092 publications indexed in the Web of Science, Scopus, and PubMed databases were analyzed using CiteSpace, VOSviewer, and bibliometrix.
Comparison of the efficacy of intravascular lithotripsy and rotational atherectomy as adjunctive therapy before drug-eluting stent implantation in calcified coronary lesions (CCS- Coronary Calcification Study).
BMC Cardiovasc Disord
September 2025
Department of Applied Mathematics, Faculty of Electrical Engineering and Computer Science, VSB-Technical University of Ostrava, Ostrava, Czech Republic.
Background: This prospective randomized study compares the efficacy of novel intravascular lithotripsy (IVL) to the standard preparation of calcified coronary lesions based on rotational atherectomy (RA).
Methods: A total of 50 patients with 52 calcified lesions were enrolled in the study and randomized 1:1 to be treated with IVL or RA followed by drug-eluting stent (DES) implantation. The procedural success was chosen as a primary endpoint and the 12-month late lumen loss (LLL) as measured by quantitative coronarography, the incidence of binary in-stent restenosis (ISR), 12-month major adverse cardiac events (MACE) and target lesion failure (TLF) served as secondary angiographic and clinical endpoints.
Outcomes of Radiation Overlap and Margin Length in Intracoronary Brachytherapy for In-Stent Restenosis.
Catheter Cardiovasc Interv
September 2025
Department of Cardiology, Houston Methodist DeBakey Heart & Vascular Center, Houston, Texas, USA.
Background: In-stent restenosis (ISR) is a common complication following coronary stent implantation. Intracoronary brachytherapy (ICBT) has re-emerged as an effective treatment modality. However, optimal procedural strategies, including the role of radiation source overlap and adequate margin length, remain unclear.
View Article and Find Full Text PDFThe complex inflammatory indexes predict the prognostic risk for patients with acute coronary syndrome undergoing percutaneous coronary intervention.
BMC Immunol
September 2025
Department of Cardiology, The Affiliated Hospital of Chengde Medical University, Chengde, 067000, China.
Introduction: An accurate assessment of prognostic risk is widely recognized to be important in improving the survival of patients with acute coronary syndrome (ACS). This study aimed to investigate the roles of neutrophil-to-lymphocyte * platelet (NLPR) and neutrophil-lymphocyte (NLR) ratios with high- and (HDL-C) and low-density lipoprotein cholesterol (LDL-C) levels in predicting the risk of major adverse cardiovascular events (MACEs) in patients with ACS undergoing percutaneous coronary intervention (PCI).
Results: Overall, 1,263 patients with ACS undergoing PCI between January 2016 and December 2018 were consecutively enrolled.